LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

KindlyMD Announces Second Quarter 2024 Financial Results and Provides Shareholder Update

August 14, 2024 | Last Trade: US$1.05 0.06 -5.41
  • Company provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such as Medicare, Select Health, Medicaid, and Blue Cross Blue Shield
  • Reimbursement from insurance payors increased 163.7% sequentially and is expected to increase as a percentage of total revenue going forward
  • Reimbursements from insurance payors totaled $126,325 in first half of 2024 as compared to $0 during the first half of 2023

SALT LAKE CITY, UT / ACCESSWIRE / August 14, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced its financial results for the second quarter ended June 30, 2024 and is providing a shareholder update.

Tim Pickett, PA-C, KindlyMD Founder and CEO, stated, "During the second quarter we successfully closed on our IPO for gross proceeds of approximately $6 million. While from a total revenue perspective during the quarter we did not yet yield the return on investment from the additional working capital we received, we are very pleased with the 163.7% sequential growth in reimbursement from insurance payors. As Utah's first alternative medical treatment company to contract under the state's top insurance payors, we are laser focused on growing this segment of our revenue stream. We are now proud to provide nearly 80% of statewide comprehensive insurance coverage to the Utah community, through top providers including Medicare, Select Health, Medicaid, and Blue Cross Blue Shield, according to the 2023 Utah Health Insurance Market Report. We are working to continue this growth trend, particularly as we invest in the acquisition of new patients to our facilities."

"Our team is also focused on aggressive growth via accretive acquisitions of clinics in Utah to expand our footprint. As a leader in the market, we see significant opportunity to potentially acquire profitable locations and integrate onto our platform driving operational synergies and margin expansion. The market is highly fragmented, and our potential pipeline remains robust. We look forward to updating our shareholders on our progress in the near future."

Operational Highlights:

  • Completed IPO in June 2024 for net proceeds of $6.02 million

  • Achieved nearly 80% statewide comprehensive insurance coverage in Utah according to the 2023 Utah Health Insurance Market Report

  • Became Utah's first alternative medical treatment company to contract under the state's top insurance payors, which now include Medicare, Select Health and Medicaid and Blue Cross Blue Shield

  • Collaborated with Curaleaf to expand patient education on medical cannabis care in Utah with community care events held at multiple Curaleaf Utah medical cannabis pharmacies

  • Successfully registered on SAM.gov, the official U.S. federal funding platform

Subsequent Events:

  • Submitted a comment to the U.S. Department of Justice, following its recent proposed rule to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act

Financial Highlights for the Quarterly Period Ended June 30, 2024

The Company earned $91,553 in reimbursements from insurance payors during the three months ending June 30, 2024, an increase of 163.7% over the $34,722 earned for the three months ending March 31, 2024. The Company earned $126,325 in reimbursements from insurance payors during the six months ended June 30, 2024, as compared to $0 during the three and six months ended June 30, 2023.

Revenues decreased by $340,481, or 34.8%, to $639,057 for the three months ended June 30, 2024, from $979,538 for the three months ended June 30, 2023. The decrease in revenues is primarily attributed to a decrease in cash-pay patient care services as KindlyMD continues to shift toward insurance billing with commercial and governmental payers including Medicare, Medicaid, Select Health, Blue Cross Blue Shield, and other commercial payers compared to the prior period.

Operating expenses increased by $95,423, or 6.0%, to $1,676,250 for the three months ended June 30, 2024, from $1,580,827 for the three months ended June 30, 2023. The increase in operating expenses is primarily attributable to an increase in general and administrative expenses, salaries and wages, and cost of revenues.

Net loss per share decreased by $0.13, or 100.0%, to $(0.26) for the three months ended June 30, 2024, compared to $(0.13) for the three months ended June 30, 2023. KindlyMD management strives to look for opportunities to optimize revenue by increasing sales, acquiring additional clinics, improving margins, and controlling ongoing operating expenses.

As of June 30, 2024, the Company had cash and cash equivalents of $4.74 million and total working capital of $4.11 million.

In June 2024, KindlyMD completed its IPO for total net proceeds of $6.02 million, providing adequate liquidity and cash reserves to meet its obligations for at least the 12-month period following June 30, 2024, and to assist the Company in implementing its strategic operational business plans to create sustained cash flow generation thereafter.

As of August 9, 2024, the Company had 5,947,169 common shares outstanding.

About KindlyMD

KindlyMD™️ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers, including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.

For more information, please visit www.kindlymd.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

Investor Relations Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

KINDLY MD, INC.
CONDENSED BALANCE SHEETS

 

 

June 30, 2024

 

 

December 31, 2023

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,740,006

 

 

$

525,500

 

Accounts receivable

 

 

5,182

 

 

 

28,001

 

Inventories, net

 

 

3,825

 

 

 

63,202

 

Prepaid expenses and other current assets

 

 

305,655

 

 

 

225

 

Total Current Assets

 

 

5,054,668

 

 

 

616,928

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

206,816

 

 

 

235,292

 

Operating lease right-of-use assets

 

 

184,177

 

 

 

235,706

 

Security deposits

 

 

11,276

 

 

 

11,276

 

TOTAL ASSETS

 

$

5,456,937

 

 

$

1,099,202

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

628,749

 

 

$

329,810

 

Customer deposits

 

 

4,150

 

 

 

3,425

 

Current portion of operating lease liabilities

 

 

79,973

 

 

 

94,696

 

Current portion of finance lease liabilities

 

 

2,010

 

 

 

-

 

Current portion of notes payable, net

 

 

228,061

 

 

 

148,517

 

Derivative liability

 

 

-

 

 

 

238,000

 

Total Current Liabilities

 

 

942,943

 

 

 

814,448

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, net of current portion

 

 

124,651

 

 

 

164,295

 

Finance lease liabilities, net of current portion

 

 

8,635

 

 

 

 

 

Notes payable, net of current portion

 

 

-

 

 

 

228,871

 

TOTAL LIABILITIES

 

 

1,076,229

 

 

 

1,207,614

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity (Deficit)

 

 

 

 

 

 

 

 

Preferred Stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023

 

 

-

 

 

 

-

 

Common stock, $0.001 par value, 100,000,000 shares authorized; 5,939,516 and 4,617,798 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

 

 

5,940

 

 

 

4,618

 

Additional paid-in capital

 

 

10,134,801

 

 

 

4,045,024

 

Accumulated deficit

 

 

(5,760,033

)

 

 

(4,158,054

)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

 

 

4,380,708

 

 

 

(108,412

)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

$

5,456,937

 

 

$

1,099,202

 

KINDLY MD, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

June 30,

 

 

For the Six Months Ended

June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues

 

$

639,057

 

 

$

979,538

 

 

$

1,468,086

 

 

$

2,139,883

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

61,947

 

 

 

59,508

 

 

 

69,691

 

 

 

108,132

 

Salaries and wages

 

 

1,126,893

 

 

 

1,109,559

 

 

 

1,834,859

 

 

 

2,042,860

 

General and administrative

 

 

461,677

 

 

 

385,536

 

 

 

787,222

 

 

 

743,719

 

Depreciation

 

 

25,733

 

 

 

26,224

 

 

 

50,634

 

 

 

51,666

 

Total Operating Expenses

 

 

1,676,250

 

 

 

1,580,827

 

 

 

2,742,406

 

 

 

2,946,377

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS FROM OPERATIONS

 

 

(1,037,193

)

 

 

(601,289

)

 

 

(1,274,320

)

 

 

(806,494

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

13,828

 

 

 

13,075

 

 

 

25,868

 

 

 

37,301

 

Interest expense

 

 

(318,450

)

 

 

(8,194

)

 

 

(375,689

)

 

 

(8,194

)

Loss on extinguishment of debt

 

 

(38,889

)

 

 

 

 

 

 

(38,889

)

 

 

 

 

Gain on change in fair value of derivative liability

 

 

61,051

 

 

 

-

 

 

 

61,051

 

 

 

-

 

Total Other Income (Expenses)

 

 

(282,460

)

 

 

4,881

 

 

 

(327,659

)

 

 

29,107

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS BEFORE INCOME TAXES

 

 

(1,319,653

)

 

 

(596,408

)

 

 

(1,601,979

)

 

 

(777,387

)

INCOME TAX EXPENSE

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

NET LOSS

 

$

(1,319,653

)

 

$

(596,408

)

 

$

(1,601,979

)

 

$

(777,387

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOSS PER COMMON SHARE - BASIC AND DILUTED

 

$

(0.26

)

 

$

(0.13

)

 

$

(0.33

)

 

$

(0.17

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED

 

 

5,009,956

 

 

 

4,455,912

 

 

 

4,813,877

 

 

 

4,445,714

 

KINDLY MD, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

 

For the Six Months Ended
June 30,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$

(1,601,979

)

 

$

(777,387

)

Adjustments to reconcile loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

15,500

 

 

 

338,021

 

Depreciation expense

 

 

50,634

 

 

 

51,666

 

Loss on extinguishment of debt

 

 

38,889

 

 

 

-

 

Gain on change in fair value of derivative liability

 

 

(61,051

)

 

 

-

 

Amortization of debt discounts

 

 

357,439

 

 

 

876

 

Amortization of right-of-use assets

 

 

51,529

 

 

 

61,589

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

22,819

 

 

 

4,161

 

Inventories

 

 

59,377

 

 

 

(9,822

)

Prepaid expenses and other current assets

 

 

(305,430

)

 

 

11,039

 

Security deposits

 

 

-

 

 

 

731

 

Accounts payable and accrued expenses

 

 

298,939

 

 

 

106,668

 

Customer deposits

 

 

725

 

 

 

300

 

Operating lease liabilities

 

 

(54,367

)

 

 

(62,806

)

Net cash used in operating activities

 

 

(1,126,976

)

 

 

(274,964

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(11,182

)

 

 

(14,420

)

Net cash used in investing activities

 

 

(11,182

)

 

 

(14,420

)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Net proceeds from issuance of notes payable

 

 

45,000

 

 

 

-

 

Net proceeds from issuance of related party note payable

 

 

 

 

 

 

233,373

 

Net proceeds from issuance of common shares and warrants in connection with a public offering

 

 

5,860,650

 

 

 

-

 

Repayments of related party note payable

 

 

-

 

 

 

(20,282

)

Repayments of notes payable

 

 

(552,655

)

 

 

-

 

Repayments of finance lease liabilities

 

 

(331

)

 

 

-

 

Net cash provided by financing activities

 

 

5,352,664

 

 

 

213,091

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

4,214,506

 

 

 

(76,293

)

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS

 

 

 

 

 

 

 

 

Beginning of the period

 

 

525,500

 

 

 

186,918

 

End of the period

 

$

4,740,006

 

 

$

110,625

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

19,089

 

 

$

-

 

Cash paid for income taxes

 

$

-

 

 

$

-

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Debt discounts on notes payable

 

$

10,556

 

 

$

-

 

Debt discount on related party note payable

 

$

-

 

 

$

16,627

 

Fair value of derivative liability recognized upon issuance of notes payable

 

$

38,000

 

 

$

-

 

Extinguishment of derivative liability upon settlement of notes payable

 

$

214,949

 

 

$

-

 

Finance purchases of property and equipment

 

$

10,976

 

 

$

-

 

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB